Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
Top Page
Medicus Pharma Ltd
(NASDAQ:MDCX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.47
▼(-67.60% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.
Positive Factors
Positive Phase 2 SkinJect data
The 200-µg cohort's 73% clinical clearance in the SKNJCT-003 Phase 2 trial provides decision-grade evidence of clinical activity for the SkinJect microneedle platform. This materially strengthens the program's regulatory and partnering case, supporting end-of-phase-2 discussions and long-term commercialization prospects in BCC.
Negative Factors
Pre-revenue with widening losses and cash burn
Medicus reports no revenue and materially widening operating losses, with cash burn accelerating (notably ~-$10.2M in 2024 and ~-$22.8M in 2025). This structural cash deficit requires ongoing external financing, increasing dilution risk and constraining independent funding of development programs absent partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2 SkinJect data
The 200-µg cohort's 73% clinical clearance in the SKNJCT-003 Phase 2 trial provides decision-grade evidence of clinical activity for the SkinJect microneedle platform. This materially strengthens the program's regulatory and partnering case, supporting end-of-phase-2 discussions and long-term commercialization prospects in BCC.
Read all positive factors
Medicus Pharma Ltd (MDCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.35M
Dividend YieldN/A
Average Volume (3M)7.45M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth-55.95%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding39,362,110
10 Day Avg. Volume1,262,563
30 Day Avg. Volume7,450,726
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$6.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Medicus Pharma Ltd Business Overview & Revenue Model
Company Description
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer....
How the Company Makes Money
null...
Medicus Pharma Ltd Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
35
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -18.35M | -11.16M | -586.78K | -1.17M | -1.94M |
| Net Income | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
Balance Sheet | |||||
| Total Assets | 10.06M | 5.65M | 1.89M | 282.65K | 78.51K |
| Cash, Cash Equivalents and Short-Term Investments | 8.71M | 4.16M | 1.72M | 267.65K | 78.51K |
| Total Debt | 4.00M | 322.27K | 0.00 | 1.53M | 667.93K |
| Total Liabilities | 10.02M | 2.51M | 781.61K | 12.48M | 10.58M |
| Stockholders Equity | -67.55K | 3.13M | 1.11M | -12.20M | -10.51M |
Cash Flow | |||||
| Free Cash Flow | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Operating Cash Flow | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Investing Cash Flow | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 31.94M | 12.69M | 5.61M | 1.25M | 882.38K |
Medicus Pharma Ltd Technical Analysis
Negative
1.46
Price Trends
0.85
Negative
1.31
Negative
1.90
Negative
Market Momentum
-0.12
Negative
38.07
Neutral
63.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Negative. The current price of 1.46 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.85, and below the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 38.07 is Neutral, neither overbought nor oversold. The STOCH value of 63.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDCX.
Medicus Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $342.87M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $78.65M | -8.98 | -109.73% | ― | ― | 50.39% | |
49 Neutral | $19.80M | -0.46 | -191.12% | ― | ― | -24.38% | |
44 Neutral | $114.73M | -3.07 | -75.73% | ― | ― | 4.71% | |
42 Neutral | $18.35M | -1.64 | -2986.76% | ― | ― | -55.95% | |
41 Neutral | $25.49M | -1.76 | ― | ― | ― | 31.09% |
* Healthcare Sector Average
MDCX
Medicus Pharma Ltd
0.47
-2.88
-86.09%
OVID
Ovid Therapeutics
2.60
2.35
919.61%
JSPR
Jasper Therapeutics
0.71
-3.00
-80.94%
CGTX
Cognition Therapeutics
0.88
0.56
175.00%
NRSN
Neurosense Therapeutics Ltd.
0.72
-0.27
-27.02%
PEPG
PepGen Inc.
1.66
0.49
41.88%
Medicus Pharma Ltd Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture
Neutral
Mar 6, 2026
Medicus Pharma Ltd. disclosed that, under its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) dated February 10, 2025, it sold a total of 4,471,038 common shares to Yorkville between December 19, 2025, and March 6, 2026, for aggr...
Private Placements and FinancingRegulatory Filings and Compliance
Medicus Pharma Launches At-the-Market Equity Offering Program
Neutral
Dec 30, 2025
On December 29, 2025, Medicus Pharma Ltd. entered into an Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC to establish an at-the-market equity program allowing the company to issue and sell up to $15.35 million of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.